104 related articles for article (PubMed ID: 3465876)
1. Transient cerebral dysfunction secondary to high-dose methotrexate.
Walker RW; Allen JC; Rosen G; Caparros B
J Clin Oncol; 1986 Dec; 4(12):1845-50. PubMed ID: 3465876
[TBL] [Abstract][Full Text] [Related]
2. [A case of subacute transient cerebral dysfunction in a osteosarcoma patient following high-dose methotrexate].
Yamada K; Takahashi M; Yoshida M
Gan To Kagaku Ryoho; 2002 Mar; 29(3):469-72. PubMed ID: 11915742
[TBL] [Abstract][Full Text] [Related]
3. [Transient cerebral dysfunction induced by VCR, HD-MTX in a child with acute lymphocytic leukemia].
Sato J; Yuasa Y; Tanaka H; Ninomiya T; Hirose M; Miyao M
Rinsho Ketsueki; 1986 Nov; 27(11):2162-7. PubMed ID: 3469437
[No Abstract] [Full Text] [Related]
4. Transient cerebral dysfunction following chemotherapy for osteogenic sarcoma.
Allen JC; Rosen G
Ann Neurol; 1978 May; 3(5):441-4. PubMed ID: 310278
[TBL] [Abstract][Full Text] [Related]
5. Acute transient cerebral toxicity associated with administration of high-dose methotrexate.
Mittal R; Mottl H; Nemec J
Med Princ Pract; 2005; 14(3):202-4. PubMed ID: 15863997
[TBL] [Abstract][Full Text] [Related]
6. Necrotizing encephalopathy following intraventricular instillation of methotrexate.
Shapiro WR; Chernik NL; Posner JB
Arch Neurol; 1973 Feb; 28(2):96-102. PubMed ID: 4739170
[No Abstract] [Full Text] [Related]
7. Transient encephalopathy during the late course of treatment with high-dose methotrexate.
Fritsch G; Urban C
Cancer; 1984 May; 53(9):1849-51. PubMed ID: 6584197
[TBL] [Abstract][Full Text] [Related]
8. Highly effective reduced toxicity dose-intensive pilot protocol for non-metastatic limb osteogenic sarcoma (SCOS 89).
Shkalim-Zemer V; Ash S; Toledano H; Kollender Y; Issakov J; Yaniv I; Cohen IJ
Cancer Chemother Pharmacol; 2015 Nov; 76(5):909-16. PubMed ID: 26365289
[TBL] [Abstract][Full Text] [Related]
9. Preoperative administration of high-dose methotrexate for osteosarcoma.
Chan KW; Knowling MA; Duncan CP; Morton KS
Can J Surg; 1984 May; 27(3):305-7, 309. PubMed ID: 6586272
[TBL] [Abstract][Full Text] [Related]
10. Late magnetic resonance imaging features of leukoencephalopathy in children with central nervous system tumours following high-dose methotrexate and neuraxis radiation therapy.
Kellie SJ; Chaku J; Lockwood LR; O'Regan P; Waters KD; Wong CK;
Eur J Cancer; 2005 Jul; 41(11):1588-96. PubMed ID: 16026694
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of low-dose methotrexate in advanced osteosarcoma followed by escalation after disease progression: a study of the Soft Tissue and Bone Sarcoma Group of the European Organization for Research on Treatment of Cancer.
Wagener DJ; van Oosterom AT; Mulder JH; Somers R; Mouridsen HT; Cortes Funes H; Thomas D; Sylvester R
Cancer Treat Rep; 1986 May; 70(5):615-8. PubMed ID: 3458532
[TBL] [Abstract][Full Text] [Related]
12. Subacute encephalopathy after combination chemotherapy including moderate-dose methotrexate in a patient with gastric cancer.
Genvresse I; Dietzmann A; Massenkeil G; Späth-Schwalbe E; Possinger K
Anticancer Drugs; 1999 Mar; 10(3):293-4. PubMed ID: 10327035
[TBL] [Abstract][Full Text] [Related]
13. High dose systemic methotrexate-associated acute neurologic dysfunction.
Packer RJ; Grossman RI; Belasco JB
Med Pediatr Oncol; 1983; 11(3):159-61. PubMed ID: 6602269
[TBL] [Abstract][Full Text] [Related]
14. MR findings in methotrexate-induced CNS abnormalities.
Ebner F; Ranner G; Slavc I; Urban C; Kleinert R; Radner H; Einspieler R; Justich E
AJR Am J Roentgenol; 1989 Dec; 153(6):1283-8. PubMed ID: 2816647
[TBL] [Abstract][Full Text] [Related]
15. [Neurologic complications during chemotherapy of children with acute lymphoid leukemia].
Kardos M; Grexa E; Kajtár P
Orv Hetil; 1992 May; 133(18):1111-5. PubMed ID: 1579351
[TBL] [Abstract][Full Text] [Related]
16. Telangiectatic osteogenic sarcoma. Improved survival with combination chemotherapy.
Rosen G; Huvos AG; Marcove R; Nirenberg A
Clin Orthop Relat Res; 1986 Jun; (207):164-73. PubMed ID: 2424660
[TBL] [Abstract][Full Text] [Related]
17. Hearing loss during osteosarcoma chemotherapy: when acute ifosfamide toxicity revealed unnoticed methotrexate encephalopathy.
Robert G; Chappé C; Taque S; Bruneau B; Gandemer V
J Pediatr Hematol Oncol; 2014 Mar; 36(2):e100-2. PubMed ID: 24309600
[TBL] [Abstract][Full Text] [Related]
18. Intraventricular methotrexate as part of primary therapy for children with infant and/or metastatic medulloblastoma: Feasibility, acute toxicity and evidence for efficacy.
Pompe RS; von Bueren AO; Mynarek M; von Hoff K; Friedrich C; Kwiecien R; Treulieb W; Lindow C; Deinlein F; Fleischhack G; Kuehl J; Rutkowski S
Eur J Cancer; 2015 Nov; 51(17):2634-42. PubMed ID: 26346136
[TBL] [Abstract][Full Text] [Related]
19. Hyper-alkalinization without hyper-hydration for the prevention of high-dose methotrexate acute nephrotoxicity in patients with osteosarcoma.
Mir O; Ropert S; Babinet A; Alexandre J; Larousserie F; Durand JP; Enkaoua E; Anract P; Goldwasser F
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1059-63. PubMed ID: 20155268
[TBL] [Abstract][Full Text] [Related]
20. Bullous variant of acral erythema in a child after high-dose methotrexate.
Zils K; Wilhelm M; Reeh T; Bielack S
Pediatr Hematol Oncol; 2012 May; 29(4):378-9. PubMed ID: 22568802
[No Abstract] [Full Text] [Related]
[Next] [New Search]
